
    
      Phase 1a/Ib study will be conducted to evaluate the tolerability, safety, PK, PD,
      immunogenicity and preliminary antitumor activity of IBI322 in China. Phase 1a is dose
      escalation and plans to enroll approximately 38-60 subjects with advanced malignant solid
      tumors who failed the standard treatment. Phase Ib is dose expansion, and plans to enroll
      approximately 180 subjects with advanced malignant tumors.
    
  